Pertuzumab neoadjuvant population PK
A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.
- Therapeutic
- Pertuzumab
- Target
- HER2 / ERBB2
- Disease
- Breast cancer
Biological model
A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.
Intervention
Pertuzumab
Biological focus
HER2 / ERBB2
Context
Breast cancer
Model details
A two-compartment population PK model connecting pertuzumab dosing and lean-body-weight and albumin covariates to concentration and cumulative exposure during neoadjuvant therapy.
Modeled states
- AUC ug day mLug*day/mL
Modeled dynamic state for auc ug day ml.
- A central mgmg
Modeled dynamic state for a central mg.
- A peripheral mgmg
Modeled dynamic state for a peripheral mg.
- elapsed time dayday
Modeled dynamic state for elapsed time day.
Key readouts
- Pertuzumab concentrationunknown
Model-derived readout for pertuzumab concentration.
- Cumulative pertuzumab exposureug*day/mL
Model-derived readout for cumulative pertuzumab exposure.
- Covariate-adjusted clearanceunknown
Model-derived readout for covariate-adjusted clearance.
- Covariate-adjusted central volumeunknown
Model-derived readout for covariate-adjusted central volume.
- A central mgmg
Model-derived readout for a central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
Typical NeoSphere 840/420 mg every 3 weeks four-cycle PK shell
How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure? Explore this intervention regimen through Pertuzumab concentration, Cumulative pertuzumab exposure, Covariate-adjusted clearance, Covariate-adjusted central volume. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do regimen, lean body weight, and albumin change pertuzumab concentration and exposure?
CL L day
Model parameter controlling cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancerCancer Chemotherapy and Pharmacology
